Univariate association of clinical variables with 30-day, 1-year and total mortality in the entire cohort
| N=4111 | Mortality, N (%) | ||
|---|---|---|---|
| 30 days | 1 year | All (median 912 days) | |
| 409 (9.95) | 677 (16.47) | 1041 (25.32) | |
| Admission demographic variable | |||
| Gender (female vs male) | 0.535 (0.439 to 0.650) | 0.515 (0.443 to 0.600) | 0.554 (0.490 to 0.627) |
| Age (year) | 1.068 (1.059 to 1.078) | 1.077 (1.069 to 1.084) | 1.084 (1.077 to 1.090) |
| SBP (mm Hg) | 0.979 (0.976 to 0.983) | 0.987 (0.984 to 0.990) | 0.992 (0.990 to 0.994) |
| Heart rate (beat/min) | 1.010 (1.006 to 1.013) | 1.012 (1.009 to 1.014) | 1.012 (1.010 to 1.014) |
| Total cholesterol (mmol/l) | 0.732 (0.666 to 0.806) | 0.765 (0.712 to 0.821) | 0.744 (0.703 to 0.788) |
| Admission plasma glucose (mmol/l) | 1.072 (1.052 to 1.084) | 1.065 (1.055 to 1.076) | 1.059 (1.050 to 1.068) |
| eGFR (ml/min) | 0.956 (0.951 to 0.961) | 0.955 (0.951 to 0.959) | 0.959 (0.956 to 0.962) |
| NSTEMI vs STEMI | 0.504 (0.405 to 0.627) | 0.736 (0.629 to 0.862) | 0.939 (0.830 to 1.063) |
| Year of admission | |||
| October 2002–December 2003 | 1 | 1 | 1 |
| 2004 | 0.909 (0.688 to 1.200) | 0.846 (0.681 to 1.052) | 0.919 (0.780 to 1.082) |
| 2005 | 0.591 (0.402 to 0.870) | 0.652 (0.491 to 0.865) | 0.702 (0.564 to 0.873) |
| 2006 | 0.830 (0.592 to 1.164) | 0.696 (0.529 to 0.917) | 0.716 (0.572 to 0.897) |
| 2007 | 0.759 (0.570 to 1.010) | 0.678 (0.541 to 0.849) | 0.679 (0.558 to 0.826) |
| 2008 | 0.485 (0.338 to 0.696) | 0.551 (0.424 to 0.716) | 0.531 (0.415 to 0.680) |
| Test for linear trend (p value) | <0.001 | <0.001 | <0.001 |
| Ethnicity (South Asian vs White European) | 1.013 (0.786 to 1.304) | 0.909 (0.741 to 1.114) | 0.856 (0.725 to 1.012) |
| Medical history (yes vs no) | |||
| Smoking | 1.016 (0.819 to 1.259) | 1.049 (0.891 to 1.235) | 1.160 (1.019 to 1.320) |
| Prior diabetes | 1.400 (1.121 to 1.750) | 1.576 (1.331 to 1.865) | 1.655 (1.445 to 1.896) |
| Prior coronary heart disease* | 0.862 (0.628 to 1.182) | 0.998 (0.791 to 1.258) | 1.113 (0.931 to 1.330) |
| Prior hypertension | 1.286 (1.056 to 1.567) | 1.437 (1.232 to 1.676) | 1.472 (1.300 to 1.666) |
| Preadmission medication (yes vs no) | |||
| Aspirin | 0.746 (0.613 to 0.909) | 0.869 (0.744 to 1.015) | 0.913 (0.804 to 1.036) |
| β-Blocker | 1.385 (1.116 to 1.719) | 1.577 (1.338 to 1.859) | 1.489 (1.301 to 1.703) |
| Statin | 0.994 (0.795 to 1.245) | 1.129 (0.953 to 1.338) | 1.194 (1.041 to 1.370) |
| ACE inhibitor or ARB | 1.242 (1.002 to 1.540) | 1.467 (1.247 to 1.726) | 1.621 (1.423 to 1.847) |
| Admission treatment (yes vs no) | |||
| Initial reperfusion | 0.616 (0.507 to 0.749) | 0.540 (0.464 to 0.629) | 0.466 (0.411 to 0.527) |
| Loop diuretic | 3.457 (2.807 to 4.256) | 4.348 (3.681 to 5.136) | 4.052 (3.556 to 4.618) |
| Discharge medication (yes vs no) | |||
| Aspirin | 0.043 (0.029 to 0.062) | 0.227 (0.192 to 0.269) | 0.439 (0.386 to 0.499) |
| β-Blocker | 0.038 (0.025 to 0.058) | 0.237 (0.199 to 0.282) | 0.406 (0.357 to 0.461) |
| Statin | 0.043 (0.029 to 0.062) | 0.196 (0.165 to 0.233) | 0.344 (0.303 to 0.390) |
| ACE inhibitor or ARB | 0.047 (0.031 to 0.700) | 0.236 (0.198 to 0.281) | 0.469 (0.412 to 0.533) |
*Any of angina/myocardial infarction/percutaneous intervention (PCI)/coronary artery bypass grafting (CABG).
Data are HR (95% CI).
ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate calculated using the MDRD formula; MDRD, modification of diet in renal disease; NSTEMI, non-ST elevation myocardial infarction; SBP, systolic blood pressure; STEMI, ST elevation myocardial infarction.